$18.97
0.864.75%
At Close: -
$19.00
0.030.16%
After Hours: 7:06 PM EDT
15 minutes delayed
Comments
Loading...
10x Genomics
TXGNASDAQ
10x Genomics (NASDAQ:TXG) Stock, Analyst Ratings, Price Targets, Forecasts
10x Genomics Inc has a consensus price target of $39.06 based on the ratings of 19 analysts. The high is $75 issued by Citigroup on August 4, 2023. The low is $16 issued by Goldman Sachs on July 9, 2024. The 3 most-recent analyst ratings were released by Canaccord Genuity, Jefferies, and B of A Securities on July 23, 2024, July 22, 2024, and July 18, 2024, respectively. With an average price target of $27 between Canaccord Genuity, Jefferies, and B of A Securities, there's an implied 42.11% upside for 10x Genomics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Canaccord Genuity
Jefferies
B of A Securities
JP Morgan
Stifel
1calculated from analyst ratings
Analyst Ratings for 10x Genomics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 07/23/2024 | Buy Now | 68.43% | Canaccord Genuity | Kyle Mikson | $50 → $32 | Maintains | Buy | Get Alert |
| 07/22/2024 | Buy Now | 26.32% | Jefferies | Tycho Peterson | $24 → $24 | Upgrade | Hold → Buy | Get Alert |
| 07/18/2024 | Buy Now | 31.58% | B of A Securities | Derik De Bruin | $36 → $25 | Maintains | Neutral | Get Alert |
| 07/18/2024 | Buy Now | 5.27% | JP Morgan | Rachel Vatnsdal | $40 → $20 | Downgrade | Overweight → Neutral | Get Alert |
| 07/16/2024 | Buy Now | 31.58% | Stifel | Daniel Arias | $53 → $25 | Maintains | Buy | Get Alert |
| 07/10/2024 | Buy Now | 31.58% | Deutsche Bank | Justin Bowers | $55 → $25 | Downgrade | Buy → Hold | Get Alert |
| 07/09/2024 | Buy Now | -15.79% | Goldman Sachs | Matthew Sykes | $26 → $16 | Maintains | Sell | Get Alert |
| 06/28/2024 | Buy Now | 26.32% | Barclays | Luke Sergott | $36 → $24 | Maintains | Overweight | Get Alert |
| 06/27/2024 | Buy Now | — | Wolfe Research | Doug Schenkel | — | Downgrade | Outperform → Peer Perform | Get Alert |
| 06/26/2024 | Buy Now | — | Guggenheim | Subbu Nambi | — | Downgrade | Buy → Neutral | Get Alert |
| 06/25/2024 | Buy Now | — | Guggenheim | Subbu Nambi | — | Downgrade | Buy → Neutral | Get Alert |
| 06/03/2024 | Buy Now | 26.32% | Jefferies | Tycho Peterson | — | Initiates | → Hold | Get Alert |
| 05/01/2024 | Buy Now | 57.9% | UBS | Dan Leonard | $52 → $30 | Maintains | Neutral | Get Alert |
| 05/01/2024 | Buy Now | 89.48% | B of A Securities | Derik De Bruin | $45 → $36 | Maintains | Neutral | Get Alert |
| 05/01/2024 | Buy Now | 36.85% | Goldman Sachs | Matthew Sykes | $30 → $26 | Maintains | Sell | Get Alert |
| 05/01/2024 | Buy Now | 68.43% | TD Cowen | Dan Brennan | $57 → $32 | Downgrade | Buy → Hold | Get Alert |
| 05/01/2024 | Buy Now | 178.95% | Stifel | Daniel Arias | $63 → $53 | Maintains | Buy | Get Alert |
| 04/29/2024 | Buy Now | 163.16% | Canaccord Genuity | Kyle Mikson | $65 → $50 | Maintains | Buy | Get Alert |
| 04/18/2024 | Buy Now | 189.48% | Deutsche Bank | Justin Bowers | $60 → $55 | Maintains | Buy | Get Alert |
| 04/10/2024 | Buy Now | 136.85% | Barclays | Luke Sergott | $55 → $45 | Maintains | Overweight | Get Alert |
| 02/16/2024 | Buy Now | 231.59% | Stifel | Daniel Arias | $68 → $63 | Maintains | Buy | Get Alert |
| 01/25/2024 | Buy Now | 189.48% | Barclays | Luke Sergott | $45 → $55 | Maintains | Overweight | Get Alert |
| 12/14/2023 | Buy Now | 215.8% | Guggenheim | Subbu Nambi | → $60 | Initiates | → Buy | Get Alert |
| 12/13/2023 | Buy Now | — | Wolfe Research | Doug Schenkel | — | Initiates | → Outperform | Get Alert |
| 12/12/2023 | Buy Now | 184.22% | B of A Securities | Derik De Bruin | $36 → $54 | Upgrade | Underperform → Neutral | Get Alert |
| 09/29/2023 | Buy Now | 147.37% | Barclays | Luke Sergott | $66 → $47 | Maintains | Overweight | Get Alert |
| 09/19/2023 | Buy Now | 268.43% | Canaccord Genuity | Kyle Mikson | → $70 | Reiterates | Buy → Buy | Get Alert |
| 08/07/2023 | Buy Now | 242.11% | Morgan Stanley | Tejas Savant | $65 → $65 | Reiterates | Overweight → Overweight | Get Alert |
| 08/04/2023 | Buy Now | 247.38% | Barclays | Luke Sergott | $65 → $66 | Maintains | Overweight | Get Alert |
| 08/04/2023 | Buy Now | 294.75% | Citigroup | Patrick Donnelly | $65 → $75 | Maintains | Buy | Get Alert |
| 07/13/2023 | Buy Now | 57.9% | Goldman Sachs | Matthew Sykes | $25 → $30 | Maintains | Sell | Get Alert |
| 05/18/2023 | Buy Now | 242.11% | Stephens & Co. | Mason Carrico | → $65 | Reiterates | Overweight → Overweight | Get Alert |
| 05/10/2023 | Buy Now | 242.11% | Barclays | Luke Sergott | → $65 | Initiates | → Overweight | Get Alert |
| 05/04/2023 | Buy Now | 257.9% | Stifel | Daniel Arias | $57 → $68 | Maintains | Buy | Get Alert |
| 05/04/2023 | Buy Now | 247.38% | TD Cowen | Dan Brennan | $62 → $66 | Maintains | Outperform | Get Alert |
| 05/04/2023 | Buy Now | 242.11% | Canaccord Genuity | Kyle Mikson | $58 → $65 | Maintains | Buy | Get Alert |
| 05/04/2023 | Buy Now | 242.11% | Stephens & Co. | Mason Carrico | → $65 | Reiterates | → Overweight | Get Alert |
| 03/31/2023 | Buy Now | 242.11% | Stephens & Co. | Mason Carrico | → $65 | Initiates | → Overweight | Get Alert |
| 02/16/2023 | Buy Now | 242.11% | Morgan Stanley | Tejas Savant | $64 → $65 | Maintains | Overweight | Get Alert |
| 02/16/2023 | Buy Now | 205.27% | Canaccord Genuity | Kyle Mikson | $55 → $58 | Maintains | Buy | Get Alert |
| 02/16/2023 | Buy Now | 200.01% | Cowen & Co. | Dan Brennan | $52 → $57 | Maintains | Outperform | Get Alert |
| 02/02/2023 | Buy Now | 163.16% | UBS | John Sourbeer | → $50 | Initiates | → Neutral | Get Alert |
| 12/14/2022 | Buy Now | 163.16% | Deutsche Bank | Justin Bowers | → $50 | Initiates | → Buy | Get Alert |
| 11/04/2022 | Buy Now | 236.85% | Morgan Stanley | Tejas Savant | $70 → $64 | Maintains | Overweight | Get Alert |
| 10/13/2022 | Buy Now | 31.58% | Goldman Sachs | Matthew Sykes | $35 → $25 | Maintains | Sell | Get Alert |
| 08/18/2022 | Buy Now | 84.22% | Goldman Sachs | Matthew Sykes | $55 → $35 | Downgrade | Neutral → Sell | Get Alert |
| 08/10/2022 | Buy Now | 268.43% | Morgan Stanley | Tejas Savant | $100 → $70 | Maintains | Overweight | Get Alert |
| 07/15/2022 | Buy Now | 163.16% | Cowen & Co. | Dan Brennan | $90 → $50 | Maintains | Outperform | Get Alert |
| 07/15/2022 | Buy Now | 84.22% | B of A Securities | Derik De Bruin | $80 → $35 | Downgrade | Neutral → Underperform | Get Alert |
| 07/15/2022 | Buy Now | — | William Blair | Brian Weinstein | — | Downgrade | Outperform → Market Perform | Get Alert |
| 07/14/2022 | Buy Now | 215.8% | Goldman Sachs | Amit Hazan | $80 → $60 | Maintains | Neutral | Get Alert |
| 05/06/2022 | Buy Now | 426.33% | Morgan Stanley | Tejas Savant | $135 → $100 | Maintains | Overweight | Get Alert |
| 05/05/2022 | Buy Now | 426.33% | Citigroup | Patrick Donnelly | $150 → $100 | Maintains | Buy | Get Alert |
| 04/13/2022 | Buy Now | 347.38% | Goldman Sachs | Amit Hazan | $95 → $85 | Maintains | Neutral | Get Alert |
| 02/17/2022 | Buy Now | 689.49% | Citigroup | Patrick Donnelly | $175 → $150 | Maintains | Buy | Get Alert |
| 11/04/2021 | Buy Now | 978.98% | Morgan Stanley | Tejas Savant | — | Maintains | Overweight | Get Alert |
| 09/14/2021 | Buy Now | 847.39% | B of A Securities | Derik De Bruin | — | Downgrade | Buy → Neutral | Get Alert |
| 08/05/2021 | Buy Now | 1057.93% | Citigroup | Patrick Donnelly | — | Maintains | Buy | Get Alert |
FAQ
What is the target price for 10x Genomics (TXG) stock?
The latest price target for 10x Genomics (NASDAQ:TXG) was reported by Canaccord Genuity on July 23, 2024. The analyst firm set a price target for $32.00 expecting TXG to rise to within 12 months (a possible 68.43% upside). 30 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for 10x Genomics (TXG)?
The latest analyst rating for 10x Genomics (NASDAQ:TXG) was provided by Canaccord Genuity, and 10x Genomics maintained their buy rating.
When was the last upgrade for 10x Genomics (TXG)?
The last upgrade for 10x Genomics Inc happened on July 22, 2024 when Jefferies raised their price target to $24. Jefferies previously had a hold for 10x Genomics Inc.
When was the last downgrade for 10x Genomics (TXG)?
The last downgrade for 10x Genomics Inc happened on July 18, 2024 when JP Morgan changed their price target from $40 to $20 for 10x Genomics Inc.
When is the next analyst rating going to be posted or updated for 10x Genomics (TXG)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of 10x Genomics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for 10x Genomics was filed on July 23, 2024 so you should expect the next rating to be made available sometime around July 23, 2025.
Is the Analyst Rating 10x Genomics (TXG) correct?
While ratings are subjective and will change, the latest 10x Genomics (TXG) rating was a maintained with a price target of $50.00 to $32.00. The current price 10x Genomics (TXG) is trading at is $19.00, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.